#United States #Cambridge #Type 1 Diabetes #GentiBio #GNTI-122

GentiBio Initiates PROMISING POLARIS Phase 1 Trial for Type 1 Diabetes

GentiBio, Inc., a biotechnology firm at the forefront of developing engineered regulatory T cell (EngTreg) therapies, has announced a significant advancement in diabetes treatment. Recently, they marked a milestone by dosing the first patient in the POLARIS Phase 1 clinical trial. This trial focuses on GNTI-122, an innovative, single-dose autologous EngTreg therapy specifically aimed at adults recently diagnosed with type 1 diabetes (T1D).

The primary objective of GNTI-122 is to mitigate or potentially eliminate the necessity for lifelong insulin therapy for individuals newly diagnosed with T1D. “This represents a critical point not only for GentiBio but also for the field of engineered immune tolerance,” asserts Mark Bach, Chief Medical Officer at GentiBio. The initiation of this trial opens doors to the possibility of preserving the body's natural insulin production through targeted immune regulation.

As type 1 diabetes can have an immediate and profound impact on daily life, the ability to halt its progression at the onset presents a transformative leap in patient care. Investigators John Buse, MD, PhD, and Klara Klein, MD, PhD from the University of North Carolina, Chapel Hill, emphasize that stopping the disease early can drastically enhance the quality of life for those living with T1D. “GNTI-122 offers a completely new strategy for protecting the insulin-producing cells of the pancreas. We are thrilled to contribute to this program,” they stated.

The POLARIS Trial: Study Design and Goals

The POLARIS trial is a Phase 1, open-label study enrolling adults aged 18 to 45 years who have been diagnosed with T1D within the past 120 days. Participants in this trial will be monitored over a span of 78 weeks to assess the safety, tolerability, and key efficacy biomarkers associated with GNTI-122. This clinical trial is taking place at ten specialized clinical sites across the U.S., with patient dosing already initiated at the University of North Carolina, Chapel Hill.

GNTI-122 is designed to counteract the hyper-inflammatory environment caused by T1D, which hampers the efficacy of the body's natural regulatory T cells (Tregs). GentiBio’s EngTreg platform has shown promise in generating robust, long-lasting, and functional Tregs that specifically target pancreatic cells. The ultimate aim is to halt the autoimmune assault that disrupts insulin production and supports long-term insulin independence for patients.

By addressing a fundamental cause of type 1 diabetes, GentiBio is positioning GNTI-122 not just as a treatment but as a potential cure. The company plans to disclose critical insights gathered from the POLARIS study toward the end of 2026 and in the early months of 2027. This research could redefine the therapeutic landscape for T1D, offering a truly innovative approach to managing and potentially curing this condition.

Conclusion

In conclusion, GentiBio’s foray into the clinical evaluation of GNTI-122 showcases tremendous promise for individuals recently diagnosed with type 1 diabetes. The POLARIS trial signifies a landmark step in the quest for therapies that can significantly alter the trajectory of T1D, aiming to empower patients with healthier, insulin-independent lives. As GentiBio moves forward, the biomedical community watches closely for results that could change the future for those affected by this challenging autoimmune disease.